Bristol-Myers Squibb Company is undervalued ... Due to the negative earnings per share, we can't calculate a P/E ratio right now. Instead, we can look at the price-to-free-cash-flow, which ...

Our free stock report includes 3 warning signs investors should be aware of before investing in Bristol-Myers Squibb. Read for free ... expected to decline by 4.9% p.a. on average during the ...

Bristol Myers Squibb (BMY) came out with quarterly earnings ... lost about 14.2% since the beginning of the year versus the S&P 500's decline of -8.6%. What's Next for Bristol Myers?

Bristol-Myers Squibb Company or BMS (BMY ... which puts its forward non-GAAP price-to-earnings (P/E) ratio at just 6.9x. For context, the last time I checked, its P/E for 2025 stood at 8.3x.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bristol-Myers Squibb (BMY – Research Report) and ...

Bristol Myers Squibb (NYSE:BMY) is scheduled to release ... portfolio presents an alternative – having outperformed the S&P 500 and generated returns exceeding 91% since its inception.

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported first-quarter net income of $2.46 billion, after reporting a loss in the same period a year earlier.

The S&P 500 also rose, gaining ... In trading on Thursday, consumer staples fell by 1.2%. Bristol Myers Squibb & Co BMY reported better-than-expected first-quarter results. The company posted ...